1. Home
  2. LI vs VTRS Comparison

LI vs VTRS Comparison

Compare LI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Li Auto Inc.

LI

Li Auto Inc.

HOLD

Current Price

$17.66

Market Cap

18.3B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$14.77

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LI
VTRS
Founded
2015
1961
Country
China
United States
Employees
30728
30000
Industry
Auto Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.3B
17.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LI
VTRS
Price
$17.66
$14.77
Analyst Decision
Hold
Buy
Analyst Count
10
4
Target Price
$19.66
$13.50
AVG Volume (30 Days)
2.6M
8.0M
Earning Date
05-28-2026
05-07-2026
Dividend Yield
N/A
3.24%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$18.98
$4.41
Revenue Next Year
$22.72
$1.96
P/E Ratio
$29.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.71
$8.19
52 Week High
$32.03
$16.47

Technical Indicators

Market Signals
Indicator
LI
VTRS
Relative Strength Index (RSI) 43.28 60.66
Support Level $17.45 $12.90
Resistance Level $18.94 $15.22
Average True Range (ATR) 0.33 0.40
MACD -0.11 0.11
Stochastic Oscillator 20.29 74.86

Price Performance

Historical Comparison
LI
VTRS

About LI Li Auto Inc.

Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: